Skip to main content

Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management across the European Union (PERFORM)

Project/agreement No.
Project funding
299 375.00 EUR
Project realization
01.01.2016. - 30.06.2021.


The primary aim is the improvement of diagnostics and care of febrile patients, which are a significant burden and responsibility of a number of both primary, as well as tertiary health care facilities, with the aim to identify and apply promising new markers, both biological and clinical phenotypic – in viral and bacterial differential diagnostics


The project also aims to differentiate between bacterial and viral infections by confirming the most accurate of them. A potential group of patients (primary, secondary and tertiary care) will be studied and a comprehensive fever management plan suitable for health care systems across the Europe will be developed

During the study, access to febrile patients will take place at phenotypic, transcryptomic (Genome and Proteome) and bioinformatics level that will characterize multi-national cohort of patients at a large-scale. In addition, study data of past large-scale multi-national studies will be used

Project lead partner

  • Imperial College of Science, Technology and Medicine (UK)


  • London School of Hygiene and Tropical Medicine (LSHTM) (UK)
  • The University of Liverpool (LIV) (UK)

  • The Chancellor, Masters and Scholars of the University of Oxford (UOXF) (UK)

  • University of Newcastle Upon Tyne (UNEW) (UK)

  • Erasmus Universitair Medisch Centrum Rotterdam (EMC) (The Netherlands)

  • Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC) (The Netherlands)

  • Stichting Katholieke Universiteit (RUMC) (The Netherlands)

  • Ethniko kai Kapodistriako Panepistimio Athinon (NKUA) (Greece)

  • Servizo Galego De Saude (SERGAS) (Spain)

  • Medizinische Universitat Graz (MUG) (Austria)

  • Univerzitetni Klinicni Center Ljubljana (UKCL) (Slovenia)

  • Rīga Stradiņš University (Latvia)

  • Medical Research Council (MRC) (UK)

  • Micropathology Limited (MIC) (UK)

  • Biomerieux SA (France)

  • Ludwig-Maximilians-Universitaet Muenchen (LMU Muenchen) (Germany)

  • Universitaet Bern (UBERN) (Switzerland)